Technical Analysis for CLVS - Clovis Oncology, Inc.

Grade Last Price % Change Price Change
grade F 5.14 -3.75% -0.20
CLVS closed down 3.75 percent on Wednesday, September 18, 2019, on 1.43 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CLVS trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish -3.75%
20 DMA Resistance Bearish -9.03%
Fell Below 20 DMA Bearish -4.99%
Bearish Engulfing Bearish -9.98%
1,2,3 Retracement Bearish Bearish Swing Setup -9.98%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -9.98%
20 DMA Support Bullish -9.98%
Outside Day Range Expansion -9.98%
Pocket Pivot Bullish Swing Setup -14.76%
Doji - Bearish? Reversal -14.76%

Older signals for CLVS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has two clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, which is Phase I/II study is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is the subject of a development program for the treatment of non-small cell lung cancer in patients with activating EGFR mutations, as well as the primary resistance mutation, T790M; and rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase that is being explored in Phase I/II clinical trials for ovarian and breast cancer patients with BRCA mutations and other DNA repair deficiencies. The company's drug discovery program includes its mutant cKit inhibitor discovery program targeting the resistance mutations that occur in the majority of gastrointestinal stromal tumor patients and result in disease progression. It has license agreements with Avila Therapeutics, Inc. and Pfizer Inc.; a drug discovery collaboration agreement with Array BioPharma Inc.; and collaborations with Roche Molecular Systems and Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Biopharmaceutical Disease Chemical Compounds Organic Compounds Drug Discovery Breast Cancer Non Small Cell Lung Cancer Lung Cancer Treatment Of Non Small Cell Lung Cancer Epidermal Growth Factor Receptor Lactams Indoles Gastrointestinal Stromal Tumor Heterocyclic Compounds
Is CLVS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 34.63
52 Week Low 4.98
Average Volume 3,511,411
200-Day Moving Average 17.674
50-Day Moving Average 7.9226
20-Day Moving Average 5.596
10-Day Moving Average 5.506
Average True Range 0.491
ADX 45.44
+DI 13.8211
-DI 30.717
Chandelier Exit (Long, 3 ATRs ) 4.727
Chandelier Exit (Short, 3 ATRs ) 6.473
Upper Bollinger Band 6.2428
Lower Bollinger Band 4.9492
Percent B (%b) 0.15
BandWidth 23.116512
MACD Line -0.6419
MACD Signal Line -0.8201
MACD Histogram 0.1781
Fundamentals Value
Market Cap 251.02 Million
Num Shares 48.8 Million
EPS -8.90
Price-to-Earnings (P/E) Ratio -0.58
Price-to-Sales 167.14
Price-to-Book 10.56
PEG Ratio 0.12
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.66
Resistance 3 (R3) 5.67 5.51 5.57
Resistance 2 (R2) 5.51 5.38 5.50 5.54
Resistance 1 (R1) 5.32 5.29 5.24 5.31 5.51
Pivot Point 5.16 5.16 5.12 5.16 5.16
Support 1 (S1) 4.98 5.03 4.90 4.97 4.77
Support 2 (S2) 4.82 4.95 4.81 4.74
Support 3 (S3) 4.63 4.82 4.71
Support 4 (S4) 4.62